2.76
-0.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neuphoria Therapeutics
From its filings with the US Securities and Exchange Commission
Neuphoria Therapeutics is based in Burlington, Massachusetts and is incorporated in Australia. Its shares trade on Nasdaq under the ticker NEUP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $1.2m and a net loss of $13.5m. At that date it held total assets of $28.7m and shareholders' equity of $24.6m.
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs. We are currently conducting limited active internal research and development activities focused on our alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio.
Our lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. On October 20, 2025, we announced that AFFIRM-1, our Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder ("SAD"), did not meet its primary endpoint, and secondary endpoint analysis did not show statistically significant differences or improvement over placebo. We discontinued the BNC210 SAD program and did not initiate the planned AFFIRM-2 trial. We subsequently maintained clinical readiness of the BNC210 program for post-traumatic stress disorder ("PTSD") but paused the planned SYMPHONY Phase 2b/3 trial pending the strategic transaction review process and subsequent planned merger transaction with Scancell.
Quoted from its 10-K, filed 18 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Dec 1999
- Employees
- 8
- Website
- neuphoriatx.com ↗
- Head office
- 100 SUMMIT DR, BURLINGTON, MA, 01803
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Alan FisherNon-Executive Independent Chairman of the BoardA$87,000
- Mr. Spyridon PapapetropoulosPresident, Chief Executive OfficerA$919,771
- Mr. Timothy CunninghamChief Financial Officer
- Ms. Liz DoolinVice President - Clinical DevelopmentA$357,028
- Dr. Errol De SouzaNon-Executive Director, since 2008A$3.1m
- Mr. Aaron WeaverIndependent DirectorA$77,000
- Mr. Peter DaviesNon-Executive Independent DirectorA$77,000
- Dr. Jane RyanNon-Executive Independent DirectorA$86,723
- Mr. David WilsonNon-Executive Independent DirectorA$87,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 40
- Social
- 61
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neuphoria Therapeutics Inc. operates in the Health Care sector with a focus on Biotechnology industry.
- The company's lead drug candidate BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor.
- BNC210 is designed for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD).
Weaknesses
- Neuphoria Therapeutics Inc. has only 8 employees as of the provided data.
- The company is a clinical-stage biotechnology firm with no commercialized products yet.
- The IPO occurred in December 1999, indicating a long history without significant recent market activity.
Opportunities
- The company's pipeline includes α7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2 preclinical programs.
- BNC210 addresses neuropsychiatric disorders with a focus on social anxiety disorder (SAD) and PTSD.
- The company is headquartered in Burlington, Massachusetts, a location with a strong biotechnology ecosystem.
Threats
- The biotechnology industry faces high regulatory hurdles for drug approvals.
- The company's clinical-stage status means it is vulnerable to development failures.
- The lack of commercialized products may limit revenue streams until clinical trials succeed.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.